Equity Profile
Post-Earnings Recap
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.29 | N/A | -826.87% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.29 | N/A | -826.87% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the challenges faced this quarter but emphasized their commitment to pipeline development. They did not provide updated guidance.
Management did not provide specific revenue guidance for the upcoming quarters.
The company is focusing on advancing its pipeline despite the EPS miss.
Ionis Pharmaceuticals reported a loss per share that was significantly below expectations, but the stock still saw a slight increase of 1.26%. This could indicate that investors are optimistic about the company's future pipeline despite the EPS miss. The lack of revenue guidance may leave some investors cautious, but the focus on advancing their projects is a positive sign.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
Vistra Corp.